A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Inclusion Criteria:

* Older than 18 years of age, of any race, and gender;
* Diagnosis of histologically confirmed relapsed or recurrent colorectal carcinoma that has progressed on at least first-line therapy;
* Must have a computed tomography (CT) or magnetic resonance imaging (MRI) scan performed at some point during their immediate prior treatment or observation in order to determine tumor growth rate;
* Must have measurable disease on a CT or MRI study, performed during Screening;
* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of \<=2 and a minimum life expectancy of ≥4 months;
* Must have adequate organ function within 3 weeks prior to treatment assignment

Exclusion Criteria:

* History of another malignancy;
* Known treated or untreated leptomeningeal metastasis, or a metastatic central nervous system lesion;
* Surgery within 3 weeks;
* Radiation therapy within 6 weeks;
* A history of uncontrolled diabetes mellitus, defined as a hemoglobin A1C of \>7.5% in a participant with known diabetes mellitus;
* A recent myocardial infarction (within the past year); or a participant who at the time of Screening presents with unstable or uncontrolled angina, New York Heart Association Class III or IV congestive heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram abnormality;
* An active infection;
* Has clinically significant hepatitis at Screening, or is hepatitis C antibody positive, hepatitis B surface antigen positive, or human immunodeficiency virus (HIV) seropositive.